Boston Scientific Corporation (BSX) recently entered into a definitive agreement to acquire Bolt Medical, Inc. — an intravascular lithotripsy (IVL) advanced laser-based platform developer. The acquisition will expand Boston Scientific’s cardiovascular portfolio with Bolt IVL — a complementary and differentiated calcium modification platform.Boston Scientific anticipates the transaction to be completed in the first half of 2025, subject to customary closing conditions.Likely Trend of BSX Stock Following the ...

Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary and peripheral diseaseMARLBOROUGH, Mass., Jan. 8, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for the treatment of coronary and peripheral artery disease." ...

Boston Scientific (BSX) is gaining from new product launches and accretive acquisitions. Yet, unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving BSX SharesBoston Scientific’s Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options. Particularly, the company is gaining market share, driven by the above-market growth of AXIOS an ...

The most recent trading session ended with Boston Scientific (BSX) standing at $91.29, reflecting a +0.66% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a gain of 0.55% for the day. Elsewhere, the Dow lost 0.06%, while the tech-heavy Nasdaq added 1.24%.Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on February 5, 2025. On ...

U.S. stock markets witnessed an impressive rally in 2024 after an astonishing bull run in 2023. Following the 24.2% ascent in 2023, the S&P 500 rallied 23.3% last year. The benchmark jumped 53% in the last two years recording its best performance since the nearly 66% rally in 1997-98. The broad-market index posted 57 all-time highs in 2024. The Dow and the Nasdaq Composite rallied 12.9% and 28.6%, respectively, last year.Wall Street’s rally of 2023 was predominantly dominated by the technology sector, espec ...

The Zacks Medical space comprises a diversified set of players, ranging from health insurers, hospitals and nursing homes to medical device companies. With a few days left for 2024 to conclude, factors such as a strong membership base, rising patient volumes, resumption of elective procedures, continued incidence of mental health issues and technology advancements played a pivotal role in shaping the performance of the sector so far this year. However, the persistence of inflationary challenges continued to ...

The latest trading session saw Boston Scientific (BSX) ending at $89.86, denoting a +1.02% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.73%. At the same time, the Dow added 0.16%, and the tech-heavy Nasdaq gained 0.98%.Heading into today, shares of the medical device manufacturer had lost 1.17% over the past month, outpacing the Medical sector's loss of 3.8% and lagging the S&P 500's gain of 0.34% in that time.Investors will be eagerly watching for the performance o ...

Boston Scientific (BSX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Indi ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Boston Scientific currently has an average brokerage re ...

Boston Scientific (BSX) has been gaining from new product launches and accretive acquisitions. Yet, unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving BSX SharesWe are particularly impressed by Boston Scientific’s recent acquisitions that have added numerous products (though many are under development) with immense potential. This, in turn, should help boost the top line in the long term.The company’s recently-comp ...